Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Cohort Study of Patients With Hormone Receptor-positive Metastatic Breast Cancer Treated With Palbociclib (Ibrance(Registered)) as Part of the United Kingdom Ibrance (Registered) Patient Program (IPP); the Real Outcomes Ibrance (Registered) Study (ROIS)

NCT03921866 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03921866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03921866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Cohort Study of Patients With Hormone Receptor-positive Metastatic Breast Cancer Treated With Palbociclib (Ibrance(Registered)) as Part of the United Kingdom Ibrance (Registered) Patient Program (IPP); the Real Outcomes Ibrance (Registered) Study (ROIS)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
March 1, 2019
Completion date
March 4, 2021
Enrollment
191 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hr+/her2- locally advanced, metastatic breast cancer